Remibrutinib
CLOU064A2304
Phase 3 small_molecule active
Quick answer
Remibrutinib for Chronic Spontaneous Urticaria is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Chronic Spontaneous Urticaria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active